Compliance Plan Update Reporting for March & April 2022 Quality Committee
Trust received approval for transition from SOF 4 to SOF 3, exited Recovery Support Programme. Detailed progress against 2022/23 Compliance Plan, incorporating new actions from CQC report. Oversight meetings canceled, all actions have deadlines. Board approved plan, highlighted at Big Conversation e
0 views • 11 slides
Therapeutic Trials in HIV/HCV Coinfection: ION-4, Ally-2, and Viroteam 2015
In the study of therapeutic trials in HIV/HCV coinfection between 2014-2015, notable trials included ION-4 with LDV/SOF treatment for 12 weeks in HCV/HIV co-infection patients, showing high SVR rates in both treatment-naive and experienced patients. Another trial, Ally-2, involved Daclatasvir and So
0 views • 15 slides
Comparison of SOF+RBV vs PEG-IFN-2a+RBV for HCV Genotype 2 and 3 Treatment
FISSION Study compared the efficacy of SOF+RBV and PEG-IFN-2a+RBV for HCV genotypes 2 and 3 in treatment-naive patients with chronic HCV infection. The study included 256 participants in the SOF+RBV group and 243 in the PEG-IFN-2a+RBV group. The primary objective was to determine the non-inferiority
0 views • 6 slides